Analyzing our results we can conclude that, as recommended by all the international guidelines, both chemotherapy and EGFR-TKI are equal treatment options for NSCLC patients who progressed to first-line platinum-based chemotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.